pharma · Relapsed or Refractory Multiple Myeloma (RRMM) · Relapsed and/or Refractory Multiple Myeloma
Celgene
Celgene Europe Limited
Celgene clinical programs — 19 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Summit, USA
- Employees
- 2,104
- Programs
- 45
- Drugs
- 91
- Patents
- 0
Celgene projects
19 ClinicalTrials.gov programs sponsored by Celgene.
Celgene has 19 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ACE-536-LTFU-001
Celgene Europe Limited
myelodysplastic syndrome (MDS); beta (β)-thalassemia (THAL); myelofibrosis (MF)
1 trial -
ACE-536-MF-002
Celgene Europe Limited
Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF)
1 trial -
BB2121-MM-003
Celgene Europe Limited
Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.
1 trial -
CA0561060
Celgene Europe Limited
Myelodysplastic syndrome
1 trial -
CA057-001
Celgene Europe Limited
Relapsed or Refractory Multiple Myeloma (RRMM)
1 trial -
CA058-1019
Celgene Europe Limited
Relapsed and/or Refractory Multiple Myeloma
1 trial -
CA071-1000
Celgene Europe Limited
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1 trial -
CA073-1003
Celgene Europe Limited
Relapsed/Refractory Follicular Lymphoma
1 trial -
CA073-1020
Celgene Europe Limited
High-risk Large B-cell Lymphoma
1 trial -
CA088-1007
Celgene Europe Limited
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
1 trial -
CC-220-MM-002
Celgene Europe Limited
Relapsed or Refractory Multiple Myeloma (RRMM)
1 trial -
Cendakimab
Celgene Europe Limited
Eosinophilic esophagitis
1 trial -
FEDR-MF-002
Celgene Europe Limited
Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-essential thrombocythemia myelofibrosis
1 trial -
IM047-023
Celgene Europe Limited
Moderately to Severely Active Crohn's Disease
1 trial -
Lenalidomide
Celgene Europe Limited
B-cell Chronic Lymphocytic Leukemia
1 trial -
Ozanimod, Ozanimod
Celgene Europe Limited
Ulcerative colitis
1 trial -
Ozanimod, Ozanimod
Celgene Europe Limited
Moderately to Severely Active Crohn's Disease
1 trial -
RPC01-3203
Celgene Europe Limited
Moderately to Severely Active Crohn's Disease
1 trial -
Thalidomide
Celgene Europe Limited
Multiple Myeloma
1 trial
Frequently asked questions
How many clinical projects does Celgene have?
19 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.